Keyphrases
Critically Ill Patients
78%
Thromboprophylaxis
63%
Low Molecular Weight Heparin
48%
Ultra-low Dose
42%
Intermediate Dose
42%
Intensive Care
36%
Clinical Examination
36%
Systematic Meta-analysis
36%
Acute Kidney Injury
36%
Clinical Analysis
36%
90-day Mortality
27%
Venous Thromboembolism
25%
Venous Thromboembolism Prevention
22%
Critical Care Ultrasonography
22%
Nadroparin
21%
Confidence Interval
20%
Anti-Xa Activity
18%
Circulatory Shock
18%
Diagnostic Accuracy
18%
Mortality Prediction
18%
Prospective Observational Study
18%
Cardiac Index
18%
International Survey
18%
Patients with COVID-19
18%
FloTrac
18%
Critically Ill
18%
Critical Care Ultrasound
18%
Critical Care Outcomes
18%
Intensive Care Unit
18%
Cardiac Output Monitoring
18%
Lower Extremity Deep Venous Thrombosis
18%
Deep Clustering
18%
Error Grid Analysis
18%
Acute Atrial Fibrillation
18%
Haloperidol Decanoate
18%
Oral Intoxication
18%
Bioaccumulation
12%
Intensive Care Unit Patients
12%
Hemodynamically Unstable
12%
Area under the Receiver Operating Characteristic Curve
11%
Relative Risk
11%
Cardiac Output
10%
All-cause Mortality
9%
Major Bleeding
9%
Recurrent Venous Thromboembolism
9%
Anticoagulants
9%
Clinical Signs
9%
Placebo
7%
Risk of Bias
7%
Arterial Waveform Analysis
7%
Medicine and Dentistry
Intensive Care
100%
Clinical Examination
77%
Echography
47%
Shock (Circulatory)
40%
Venous Thromboembolism
36%
Meta-Analysis
36%
Heart Output
24%
Cohort Analysis
24%
Intensive Care Unit
24%
Anticoagulant
24%
Diagnostic Accuracy
22%
Atrial Fibrillation
22%
Observational Study
20%
Thrombosis Prevention
20%
Systematic Review
18%
Lung Auscultation
18%
Lower Extremity Deep Vein Thrombosis
18%
Network Meta-Analysis
18%
Patient-Data
18%
Haloperidol Decanoate
18%
Deep Vein Thrombosis
18%
Pulmonary Embolism
18%
Prospective Cohort Study
18%
Heart Output Measurement
18%
New-Onset Atrial Fibrillation
18%
Acute Kidney Injury
18%
Prognostic Factor
18%
Auscultation
18%
Hemodynamic
17%
Pulmonary Edema
15%
Diagnosis
12%
Direct Oral Anticoagulant
12%
Placebo
12%
Heparin
12%
Low Molecular Weight Heparin
9%
Sequential Analysis
9%
Major Bleeding
9%
Subgroup Analysis
8%
Physician
8%
Crackle
7%
Rhonchi
7%
Rhythm
7%
Arterial Pressure
7%
Activated Charcoal
7%
Ingestion
7%
Randomized Controlled Trial
6%
Antiarrhythmic Agent
6%
Adverse Event
6%
All Cause Mortality
6%
Pentasaccharide
6%
Pharmacology, Toxicology and Pharmaceutical Science
Thrombosis
83%
Venous Thromboembolism
80%
Low Molecular Weight Heparin
54%
Acute Kidney Failure
54%
Placebo
20%
Anticoagulant Agent
20%
Deep Vein Thrombosis
20%
Prospective Cohort Study
20%
Nadroparin
20%
Lung Embolism
20%
Kidney Disease
18%
All Cause Mortality
18%
Bleeding
18%
Shock
18%
Lower Extremity Deep Vein Thrombosis
18%
Haloperidol Decanoate
18%
Toxic Injury
18%
Adverse Event
15%
Direct Oral Anticoagulant
12%
Heparin
12%
Bioaccumulation
11%
Randomized Controlled Trial
10%
Activated Carbon
7%
Pentasaccharide
6%
Forward Heart Failure
6%
Replacement Therapy
5%
